GSK posts results for two trials: DREAMM 9 myeloma combo and HSV immunotherapy study

GlaxoSmithKline reported results on two long-running studies, a Phase 1 multiple myeloma combination trial and a completed Phase I/II herpes immunotherapy trial.

GSK posted results for two clinical trials this week, both first posted years earlier.

DREAMM 9 (NCT04091126), a Phase 1 trial of belantamab mafodotin added to bortezomib, lenalidomide and dexamethasone (VRd) in newly diagnosed multiple myeloma, is listed as active not recruiting with 118 participants enrolled¹. The study tested multiple dose and schedule cohorts to determine a recommended phase 3 dose in adult participants with newly diagnosed multiple myeloma¹, with primary completion recorded as 2025-06-02.
NCT05298254, a Phase I/II trial of an investigational herpes simplex virus-targeted immunotherapy, is listed as completed with primary and study completion both dated 2025-06-12. The trial was conducted in 2 parts: Part I assessing different formulations of the HSVTI in healthy participants aged 18-40 years; Part II assessing the 2 formulations of the HSVTI in participants aged 18-60 years with recurrent genital herpes², enrolling 504 participants total.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.